Changing the paradigm: How a veterinary oncologist informed knowledge of hypoxia

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Spotlight article

When a Galapagos tortoise suffering from sarcoma needed help in 1983, zookeepers at the Staten Island Zoo called Mark Dewhirst, DVM, PhD, a young scientist at the University of Arizona who had been conducting clinical trials on dogs using radiotherapy.

They were hoping radiotherapy might also help the tortoise — named Jalopy because he scooted around with the aid of a skateboard contraption after losing mobility from his many surgeries — so they shipped him Dewhirst’s way.

Dewhirst’s ingenuity in rigging up a system to treat the 80-year-old tortoise, a species he’d never treated before, lengthened the tortoise’s life and made headlines.

The grandson of farmers and the son of a science professor at University of Arizona who studied parasites in cattle, Dewhirst said he grew up around animals, first in Kansas and then in Arizona. He seemed to be destined for veterinary medicine.

After earning an undergraduate degree in chemistry from University of Arizona and doctorates in veterinary medicine (1975) and radiation biology (1979) from Colorado State University, he joined the faculty at University of Arizona. His research career spanned more than three decades, most of them at Duke.

Quote of the week

Dogs are really good models for treating with hyperthermia because, unlike mouse tumors, you encounter the same challenges of trying to heat canine tumors that you do with human tumors. I started my first trial in 1979 in Arizona and I continued to do them until my PO1 grant ran out of money in 2009 at Duke.

Mark Dewhirst 

Recent obituaries

Sanjiv Sam Gambhir, MD, PhD, professor and chair of radiology at the Stanford School of Medicine and an internationally recognized pioneer in molecular imaging, died July 18, 2020 of cancer. He was 57.

The Virginia and D.K. Ludwig Professor of Cancer Research, Gambhir dedicated his career to developing methods of early disease detection, ushering in a new era of molecular imaging to flag signals of disease in its nascent stages. He was director of the Canary Center at Stanford for Cancer Early Detection, director of the Precision Health and Integrated Diagnostics Center at Stanford and director of the Molecular Imaging Program at Stanford.

“Sam was a true visionary and a scientist of the highest caliber. His research and innovations have, with no uncertainty, founded modern medicine’s approach to early disease diagnostics and will continue to guide the future of precision health,” said Lloyd Minor, MD, dean of the School of Medicine. “Sam’s contributions to Stanford, to human health, to the science of diagnostics and to the many lives he has touched and impacted throughout his career have been immeasurable.”

Within the field of radiology, Gambhir was known for the development of positron emission tomography reporter genes, which can flag molecular activity that signals something’s gone awry in the body.

Flags were lowered to half-staff today (June 17, 2020) across Duke for Neil Spector, MD, a nationally recognized physician-scientist, translational research leader, and oncology mentor, who passed away on Sunday, June 14, 2020. He was 63.

Dr. Spector was the Sandra Coates Associate Professor in the Department of Medicine, an associate Professor of Pharmacology and Cancer Biology, and a member of the Duke Cancer Institute.

He joined Duke Cancer Institute and the faculty at Duke University School of Medicine in September 2006 after serving for eight years as director of Exploratory Medical Sciences-Oncology at GlaxoSmithKline and as adjunct associate professor of Medicine, Division of Hematology/Oncology, University of North Carolina at Chapel Hill.

Dr. Spector’s appointments at DCI include having served as associate director for Translational Research, director of the Developmental Therapeutics Program, and associate co-director of Clinical Research with the Breast Cancer disease group.

His laboratory research focused on elucidating molecular mechanisms of therapeutic resistance to targeted therapies and strategies to prevent and overcome resistance. He is credited with leading two molecularly targeted therapies to FDA approval, one for the treatment of pediatric T-cell acute lymphoblastic leukemia (nelarabine) and another for the treatment of HER2 overexpressing breast cancers (lapatinib).

A medical oncologist, Dr. Spector most recently served as an attending physician and supervised medical oncology fellows at the Durham VA Healthcare System.


This column features the latest posts to the Cancer History Project by our growing list of contributors

The Cancer History Project is a free, web-based, collaborative resource intended to mark the 50th anniversary of the National Cancer Act and designed to continue in perpetuity. The objective is to assemble a robust collection of historical documents and make them freely available. 

Access to the Cancer History Project is open to the public at CancerHistoryProject.com. You can also follow us on Twitter at @CancerHistProj, or follow our podcast.

Is your institution a contributor to the Cancer History Project? Eligible institutions include cancer centers, advocacy groups, professional societies, pharmaceutical companies, and key organizations in oncology. 

To apply to become a contributor, please contact admin@cancerhistoryproject.com.

Table of Contents

YOU MAY BE INTERESTED IN

U.S. Deputy Secretary for Health and Human Services, Andrea Palm, and Sweden's Minister for Health Care, Acko Ankarberg Johansson, signing the agreement. Credit: Joel Apelthun/Government Offices of SwedenThe United States and Sweden signed an agreement to step up collaborations in science and technology by focusing on cancer research.

Login